Newsletter
Lupin, a leading manufacturer of Active Pharmaceutical Ingredients (APIs) in India, is acquiring UK-based Renascience Pharma for ₹135 crore in a strategic push into specialty medicines.
Context: Renascience makes niche treatments like injectable antibiotics, ear drops, and oral therapies for heart and kidney issues. These drugs target chronic, hard-to-treat conditions and already have UK regulatory approvals.
Big picture: this deal gives Lupin an express entry into the UK’s high-margin specialty drug market, skipping years of R&D and regulatory hurdles.
As Indian pharma pivots from generics to value-driven innovation, this acquisition helps Lupin boost margins and expand globally.
